Descrizione del progetto
Un software innovativo per la previsione di epitopi immunogenici per i vaccini
Gli strumenti di previsione dell’immunogenicità, il software di previsione degli epitopi (EIPS, Epitope Prediction Software) e i test, sono necessari per lo sviluppo sicuro ed economico dei farmaci. Tuttavia, la precisione e il potere predittivo del software EIPS risultano limitati, con meno del 10 % degli epitopi immunogenici previsti che inducono una risposta immunitaria. L’azienda danese Immunitrack ha sviluppato un EIPS di nuova generazione di elevata previsione e che non presenta falsi positivi, come strumento per ottimizzare lo sviluppo di farmaci e vaccini. Il software identifica gli epitopi immunogenici per un vaccino, indica le proprietà immunogeniche indesiderate di un farmaco sviluppato e guida il trattamento attraverso la valutazione della risposta immunitaria. Il progetto ImmuniPrDx, finanziato dall’UE, condurrà le attività di certificazione e i test per gli utenti per la dimostrazione e la convalida, aspetti determinanti per i vantaggi agli utenti.
Obiettivo
>90% of drug and vaccine candidates fail during drug development, resulting in an average of €35M lost per drug for the pharma companies, and a slow and expensive drug development process. A major reason for failure is unwanted/lack of immune response of the drug/vaccine candidate. Thus, immunogenicity prediction tools, Epitope Prediction Software (EIPS) and assays, are important for cost-effective and safe drug development. However, available EIPS are over-predictive and limited: using the current gold standard EIPS netMHC, <10% of the predicted immunogenic epitopes induce an immune response. Immunitrack has developed a next generation EIPS - PrDx - that with high accuracy and no false positives far exceeds the performance of netMHC. PrDx, to be applied alone or in combination with our successfully commercialized immunogenicity assays, is a strong tool for streamlining drug and vaccine development, meeting user needs for multiple applications: i) identify immunogenic epitopes to be included in a vaccine; ii) identify unwanted immunogenic properties of a newly developed drug, and iii) guide treatment by assessing patient immune response. For commercialisation, PrDx must be shaped into a customer friendly format and meet regulatory demands; the goal of the Innovation project is to conduct activities related to certifications and requirements, and user tests for demonstration and validation, critical for PrDx awareness and knowledge of user benefits. Immunitrack will sell PrDx reports for drug/vaccine candidate immunogenicity screening and complementing immunogenicity assays, through direct and indirect sales with a predicted accumulated turnover of €56M 5 years post commercialization. Immunitrack has unique capacities confirmed by our 90 customers within PrDx’s target group, from Europe, US and Asia, including several top pharma companies.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
2100 KOBENHAVN
Danimarca
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.